Alexion’s Son of Soliris Aims To Takes Dosing Right Down

Alexion is setting its sights on eight-weekly dosing for its follow-up candidate to its blockbuster Soliris, testing this schedule in its new Phase III trial in patients with paroxysmal nocturnal hemoglobinuria (PNH), based on new Phase I/II data just presented at the ASH meeting in San Diego.